|
|
Volumn 2, Issue 5, 2003, Pages 273-274
|
|
Imiquimod and the treatment of cutaneous T-cell proliferative diseases: at the threshold.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMINOQUINOLINE DERIVATIVE;
ANTINEOPLASTIC AGENT;
IMIQUIMOD;
CLINICAL TRIAL;
CUTANEOUS T CELL LYMPHOMA;
DOSE RESPONSE;
DRUG ADMINISTRATION;
FEMALE;
HUMAN;
MALE;
MAXIMUM TOLERATED DOSE;
MORTALITY;
PROGNOSIS;
REVIEW;
SKIN TUMOR;
SURVIVAL RATE;
TREATMENT OUTCOME;
AMINOQUINOLINES;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG ADMINISTRATION SCHEDULE;
FEMALE;
HUMANS;
LYMPHOMA, T-CELL, CUTANEOUS;
MALE;
MAXIMUM TOLERATED DOSE;
PROGNOSIS;
SKIN NEOPLASMS;
SURVIVAL RATE;
TREATMENT OUTCOME;
MLCS;
MLOWN;
|
|
EID: 2142692247
PISSN: 15409740
EISSN: None
Source Type: Journal
DOI: 10.1111/j.1540-9740.2003.02470.x Document Type: Review |
|
Times cited : (5)
|
|
References (10)
|
